Onkure Therapeutics, INC. (OKUR) — 8-K Filings

All 8-K filings from Onkure Therapeutics, INC.. Browse 10 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (10)

8-K Filing — Mar 30, 2026
8-K Filing — Jun 26, 2025
OnKure Therapeutics Files 8-K on Security Holder Vote & Financials — May 28, 2025 Risk: low
On May 27, 2025, OnKure Therapeutics, Inc. filed an 8-K report detailing the submission of matters to a vote of security holders and financial statements. The c
OnKure Therapeutics Files 8-K: Corporate Details Updated — Dec 10, 2024 Risk: low
OnKure Therapeutics, Inc. filed an 8-K on December 10, 2024, reporting its principal executive offices located at 6707 Winchester Circle, #400, Boulder, Colorad
OnKure Therapeutics Files 8-K on Asset Deal & Equity Sales — Oct 8, 2024 Risk: medium
On October 4, 2024, OnKure Therapeutics, Inc. (formerly Reneo Pharmaceuticals, Inc.) filed an 8-K detailing several significant events. These include the comple
Reneo Pharmaceuticals Files 8-K on Shareholder Vote Matters — Oct 2, 2024 Risk: low
Reneo Pharmaceuticals, Inc. filed an 8-K on October 2, 2024, reporting on matters submitted to a vote of its security holders as of September 26, 2024. The fili
Reneo Pharmaceuticals to be Acquired by Syncona Limited — Sep 20, 2024 Risk: medium
Reneo Pharmaceuticals, Inc. announced on September 20, 2024, that it has entered into a definitive agreement to be acquired by Syncona Limited. The transaction
Reneo Pharmaceuticals Announces Board and Executive Changes — Sep 13, 2024 Risk: medium
Reneo Pharmaceuticals, Inc. announced on September 9, 2024, a change in its board of directors and executive compensation arrangements. Specifically, the compan
Reneo Pharmaceuticals Announces Definitive Agreement, Equity Sales — May 13, 2024 Risk: medium
Reneo Pharmaceuticals, Inc. announced on May 10, 2024, that it entered into a Material Definitive Agreement. The filing also disclosed unregistered sales of equ
Reneo Pharma Reports Exit/Disposal Costs, Signals Strategic Shift — Feb 23, 2024 Risk: medium
Reneo Pharmaceuticals, Inc. filed an 8-K on February 23, 2024, reporting an event on February 20, 2024, related to costs associated with exit or disposal activi

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX